50th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100316624 | TREATMENT OF FIBROSES AND LIVER DISORDERS - The present invention relates to ACE2 for the therapeutic treatment or prevention of a fibrosis or liver disorder. | 2010-12-16 |
20100316625 | STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE - Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C. | 2010-12-16 |
20100316626 | METHODS FOR TREATMENT AND DIAGNOSIS OF PSYCHIATRIC DISORDERS - A method for preventing or treating a psychiatric disorder in a mammalian subject is provided. A method for preventing or treating a psychiatric disorder in a mammalian subject is provided which comprises administering to the subject a modulator of ErbB receptor signaling in an amount effective to reduce or eliminate the psychiatric disorder in the subject or to prevent its occurrence or recurrence. A method for diagnosis of a psychiatric disorder in a mammalian subject is provided. | 2010-12-16 |
20100316627 | Human antibodies to human IL-6 receptor - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 2010-12-16 |
20100316628 | AGENTS AND METHODS FOR TREATING RESPIRATORY DISORDERS - The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory-related complications in a subject by inhibiting the release of nitric oxide from basal cells in the respiratory tract. | 2010-12-16 |
20100316629 | Use of gene expression profiling to predict survival in cancer patient - Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer. | 2010-12-16 |
20100316630 | ANTI-IDIOTYPE ANTIBODIES OF THE HUMAN MONOCLONAL ANTIBODY SC-1, AND THEIR PRODUCTION AND USE - The invention features anti-idiotype antibodies of the human monoclonal antibody SC-1, as well as methods for producing and using the anti-idiotype antibodies. | 2010-12-16 |
20100316631 | Water Soluble Curcumin-Based Compounds - The present disclosure describes the design and synthesis of a novel class of water soluble curcumin-based compounds. These water soluble curcumin-based compounds are shown to provide superior cell killing activity and exhibit increased and cell internalization solubility in aqueous solutions as compared to the free (unconjugated) curcumin. The present disclosure provides compositions for the treatment or prevention of a variety of disease states or conditions, such as but not limited to, cancer, other cell hyperproliferative disorders and chronic inflammatory conditions, said compositions comprising a water soluble curcumin-based compound. | 2010-12-16 |
20100316632 | MEANS AND METHODS FOR ENHANCING DIFFERENTIATION OF HAEMATOPOIETIC PROGENITOR CELLS - The invention provides means and method for stimulating the production of differentiated haematopoietic cells in a culture comprising haematopoietic progenitor cells, lymphocytes (preferably T-cells) and monocytes/macrophages and/or dendritic cells. The methods involve among others culturing said cells or precursors thereof in the presence of a binding molecule specific for a co-stimulatory molecule expressed on said monocytes/macrophages and/or dendritic cells or said lymphocytes (preferably T-cells). | 2010-12-16 |
20100316633 | INHIBITION OF ANGIOGENESIS - The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies. | 2010-12-16 |
20100316634 | RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS - Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. | 2010-12-16 |
20100316635 | KIT FOR DIAGNOSIS OF BREAST CANCER USING HERCEPTIN, A COMPOSITION COMPRISING HERCEPTIN AND A METHOD FOR DETECTING HERCEPTIN-SENSITIVE HER2 OVEREXPRESSED CELL USING THE SAME - A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided. | 2010-12-16 |
20100316636 | Method of Treating Rheumatoid Arthritis with an IL-6R Antibody - The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof. | 2010-12-16 |
20100316637 | Compositions and Methods for Diagnosing and Treating Cancer - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 2010-12-16 |
20100316638 | Antibody Formulations and Use Thereof - The present invention is directed to combination formulations of monoclonal antibodies with anti-inflammatory agents, related methods and uses thereof. | 2010-12-16 |
20100316639 | BIOMARKERS FOR IGF-1R INHIBITOR THERAPY - The invention concerns the identification and validation of certain biomarkers for selecting patients for therapy with an IGF-1R inhibitor, particularly for breast and colorectal cancer. | 2010-12-16 |
20100316640 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 2010-12-16 |
20100316641 | ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES - Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen. | 2010-12-16 |
20100316642 | COMPLEXES OF GRP94 WITH HUMAN IMMUNOGLOBULIN G - Complexes are described that form in vitro following incubation of “Heat Shock Protein” (HSP) “Glucose-regulated Protein” 94 (Grp94) with human non-immune immunoglobulin G. Results show that complexes of Grp94-IgG are resistant to denaturing agents. Moreover, complexes display an important cytokine-like property that can be exploited to induce positive effects of immuno-modulation in pathologies characterized by either a reduced or exacerbated immune response. In addition, stability of Grp94-IgG complexes make them useful as diagnostic tools to detect antibodies directed against Grp94 in various pathological conditions. | 2010-12-16 |
20100316643 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 2010-12-16 |
20100316644 | TRUNCATED ACTRIIB-FC FUSION PROTEINS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue. | 2010-12-16 |
20100316645 | Bispecific Antigen Binding Proteins - The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2010-12-16 |
20100316646 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided. | 2010-12-16 |
20100316647 | COMPOSITIONS OF POLYPEPTIDES SPECIFIC TO PATHOGENIC STRAINS AND THEIR USE AS VACCINES AND IN IMMUNOTHERAPY - The invention relates to compositions of polypeptides specific to pathogenic strains comprising at least one polypeptide of a first group, having a sequence selected in the group comprising the sequences of SEQ ID No 159, or homologous sequences of polypeptides of the first group and/or the second group with a minimum of 25% of identity with the whole sequences of said polypeptides. Application for the preparation of vaccine compositions specific to | 2010-12-16 |
20100316648 | NOVEL PLASMINOGEN RECEPTOR, POLYPEPTIDES AND ANTIBODIES THEREOF - The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-R | 2010-12-16 |
20100316649 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) - This disclosure concerns compounds which are useful as inhibitors of spleen tyrosine kinase (Syk) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of Syk. This disclosure also relates to pharmaceutical compositions containing these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2010-12-16 |
20100316650 | SOLUBLE MIC POLYPEPTIDES AS MARKERS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR CONDITIONS - The present invention provides prognostic and diagnostic methods for cancer, as well as methods for monitoring or staging cancer. Methods involve assaying for tumor-derived soluble MIC polypeptide—either MICA or MICB or both—in a sample from a subject. Assays can be implemented with a MIC polypeptide binding agent such as a MIC polypeptide antibody or recombinantNKG2D. An ELISA sandwich assay is employed in some embodiments of the invention to identify a soluble MIC polypeptide. In additional embodiments, a sample is assayed for tumor cell-surface bound MIC in addition to assaying for soluble MIC. The invention also provides methods of cancer therapy involving detecting cancer in the subject by assaying for soluble MIC polypeptide and then administering a cancer therapy. | 2010-12-16 |
20100316651 | CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF - Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease. | 2010-12-16 |
20100316652 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2010-12-16 |
20100316653 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ORTHOPOXVIRUSES - In particular aspects, the invention provides a novel approach for the systematic analysis and identification of biologically relevant epitopes (SABRE). SABRE-identified polypeptides have diagnostic (e.g., polypeptide arrays, etc.) and/or therapeutic (e.g., vaccines, etc.) utility, and utility for developing monoclonal antibodies having diagnostic and/or therapeutic utility (e.g. for detecting and/or preventing orthopoxvirus infection). Preferred aspects provide high-throughput assays for detecting specific orthopoxvirus infection, for detecting orthopoxvirus-specific immune response, or for dual (parallel) determination of both orthopoxvirus immune response and orthopoxvirus infection. Additional preferred and surprising aspects provide novel high-throughput methods for detecting ‘protective immunity’ against orthopoxviruses (e.g., for detecting protective immunity against smallpox virus and monkeypox virus), based on anti-vaccinia virus serum antibody levels. The inventive diagnostic assays are rapid, high-throughput and suitable for ‘point-of-care’ implementations. | 2010-12-16 |
20100316654 | NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype. | 2010-12-16 |
20100316655 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY - Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure: | 2010-12-16 |
20100316656 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE - The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules. | 2010-12-16 |
20100316657 | Synthetic Archaeal Glycolipid Adjuvants - Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are obtained from appropriate Archaea. Archaeosome lipid vesicles are formulated from the synthetic lipids selected to serve as antigen carriers that target antigen-presenting cells and promote an appropriate immune response to the antigen. | 2010-12-16 |
20100316658 | METHOD FOR PRODUCING AN ANTITUMORAL VACCINE BASED ON SURFACE ENDOTHELIAL CELL ANTIGENS - Accordingly to the method of the preparing of the tumor vaccine with the use of endothelial cells, live endothelial cells are treated with a protease at mild (non-deadly for cells) conditions, the splitted surface antigens are collected, the treatment of live endothelial cells is repeated after intervals which are necessary for the recovery of the surface antigens by the cells, surface antigens are accumulated until their necessary quantity is reached, the quality of the vaccine is controlled thereafter. The technical result obtained with the use of this invention consists in the enhancement of the efficiency of oncological disease treatment due to the damage of the tumor vessels caused by overcoming of the immune tolerance of organism to the endothelial cells (EC) of tumor vessels. Here one means the overcoming of immune tolerance namely to activated EC, which allows to damage mainly to the tumor vessels by the immune system. | 2010-12-16 |
20100316659 | IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES - The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8). | 2010-12-16 |
20100316660 | EDIBLE PRODUCT HAVING AN IMMUNOSTIMULATING EFFECT - There is provided an edible product having an immunostimulating effect, said product comprising polysaccharides obtainable from the Alliaceae family of the perennial flowering plants. Also provided is a process for preparing such an edible product and composition comprising from 0.0001 to 25% by weight of polysaccharides obtainable from the Alliaceae family and having an immunostimulating effect | 2010-12-16 |
20100316661 | HIV-1 Envelope Glycoprotein Oligomer and Methods of Use - This invention relates to fusion polypeptides comprised of a trimerization domain fused to a non-membrane bound, non-cleaved gp160 polypeptide derived from the R2 HIV-1 Env glycoprotein and to compositions comprising the fusion polypeptides. This invention further relates to oligomers of the fusion polypeptides. This invention also relates to nucleic acids encoding the fusion polypeptides. This invention also relates to diagnostic and therapeutic methods using the fusion polypeptides. Further, this invention relates to the induction of cross-reactive neutralizing antibodies against HIV-1, and to immunogenic compositions for the prevention and treatment of infection by HIV-1. | 2010-12-16 |
20100316662 | Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a | 2010-12-16 |
20100316663 | Subunit Vaccine for Aquaculture - A subunit vaccine for aquaculture comprises an antigen fusion protein, and appropriate carriers or adjuvants. From amino terminal to carboxyl terminal, the antigen fusion protein comprises domain I and domain II of | 2010-12-16 |
20100316664 | Agent For Growing Fibroblasts - An agent for growing fibroblasts contains a yeast extract and a safflower extract as effective constituents. A method of growing fibroblasts comprises using a yeast extract and a safflower extract. An anti-aging agent for skin contains a yeast extract and a safflower extract as effective constituents. | 2010-12-16 |
20100316665 | PAPAYA MOSAIC VIRUS-BASED VACCINES AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS - An antigen-presenting system (APS) comprising one or more enterobacterial antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. The PapMV or VLP included in the APS is capable of potentiating an immune response against said one or more enterobacterial antigens. The APS can be used, for example, as a vaccine against enterobacterial disease, such as typhoid fever. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PapMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP), or the APS can comprise both conjugated and non-conjugated antigens. Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means. | 2010-12-16 |
20100316666 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 2010-12-16 |
20100316667 | GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF - A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine. | 2010-12-16 |
20100316668 | IMMUNOTHERAPY FOR PROSTATE CANCER USING RECOMBINANT BACILLE CALMETTE-GUERIN EXPRESSING PROSTATE SPECIFIC ANTIGENS - The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease. | 2010-12-16 |
20100316669 | VACCINE FORMULATION POTENTIATED BY THE COMBINATION OF DNA AND AN ANTIGEN - Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. | 2010-12-16 |
20100316670 | CHIMERIC SLE/DENGUE TYPE 4 ANTIGENIC VIRUSES - Embodiments described herein concern attenuated, St. Louis Encephalitis Virus/dengue virus type 4 antigenic chimeric viruses, which can be used to prepare immunogenic compositions, vaccines, and diagnostic reagents. Methods of making and using the foregoing are provided. | 2010-12-16 |
20100316671 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 2010-12-16 |
20100316672 | VACCINE - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to HIV-I envelope (Env) immunogens. | 2010-12-16 |
20100316673 | NANOEMULSION VACCINES - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic nanoemulision compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against a pathogenic virus of the paramyxoviridae family (e.g., a Paramyxovirinae virus (e.g., | 2010-12-16 |
20100316674 | Immunogenic compositions against tuberculosis - Methods of preparing mutants of | 2010-12-16 |
20100316675 | GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF OLIGOSACCHARIDES, AND GENES ENCODING THEM - The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of | 2010-12-16 |
20100316676 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases - Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as | 2010-12-16 |
20100316677 | USE OF BAMBOO LEAF TOTAL FLAVONES IN THE PREPARATION OF MEDICINE AND HEALTH FOOD FOR PREVENTION AND TREATMENT OF PROSTATIC DISEASES - This invention discloses the new uses of | 2010-12-16 |
20100316678 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN - The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology. | 2010-12-16 |
20100316679 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively. | 2010-12-16 |
20100316680 | ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS - Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines. | 2010-12-16 |
20100316681 | N-ALKYLATED RIFAMPIN - Compounds of the formula: | 2010-12-16 |
20100316682 | Biodegradable Hyaluronic Acid Derivative, Biodegradable Polymeric Micelle Composition and Pharmaceutical or Bioactive Composition - The invention provides a biodegradable hyaluronic acid derivative including at least one modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C | 2010-12-16 |
20100316683 | HYALURONIC ACID GEL FOR INTRADERMAL INJECTION - Implant that is injectable by a sub-cutaneous or intradermal route in the form of a monophasic hydrogel comprising a gel made up of cross-linked hyaluronic acid and one of its physiologically acceptable salts. | 2010-12-16 |
20100316684 | Surfactant-Free Foam Formulations - The invention relates to a foam formulation comprising an essentially emulsifier-free emulsion of the oil in water type, comprising an oil phase and a water phase. | 2010-12-16 |
20100316685 | Dental Uses of Silver Hydrosol - Microbiologically effective silver hydrosol is used to reduce the local level of microorganisms at the site of a dental procedure and to prevent or inhibit their growth during the healing that follows the procedure. Any gingival lesions created by a dental procedure are treated with silver hydrosol in an aqueous gel. Following the procedure the patient's mouth is periodically rinsed several times a day with a solution of silver hydrosol or, more preferably, with a combination of silver hydrosol and hydrogen peroxide. These steps result in a significant reduction in post operative pain and swelling. Overall healing is accelerated by this treatment. | 2010-12-16 |
20100316686 | Osteosynthesis with nano-silver - The present invention relates generally to an antibacterial coating which is composed of silver, to medical tools and to implants comprising such a coating and to a method as well to an apparatus for the production of such a coating. The medical tools or the dental or orthopaedic implant comprises a metal or metal alloy having a treated surface wherein the treated surface is at least partially converted to an oxide film by plasma electrolytic oxidation using a colloid-dispersed system and wherein the converted surface is partially covered by islands formed by colloid-dispersed silver-particles of the colloid-dispersed system. An Ag—TiO | 2010-12-16 |
20100316687 | HYDROPHOBIC POLYSACCHARIDES WITH DIESTER- OR CARBONATE ESTER-CONTAINING LINKAGES HAVING ENHANCED DEGRADATION - Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a chemistry that facilitates degradation of the polymer. Diester and carbonate ester linker chemistries are exemplified. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described. | 2010-12-16 |
20100316688 | METHODS FOR CULTURING STEM AND PROGENITOR CELLS - The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells. | 2010-12-16 |
20100316689 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 2010-12-16 |
20100316690 | Modular assembly of tissue engineered constructs - Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue. | 2010-12-16 |
20100316691 | BIODEGRADABLE INTRAVAGINAL MEDICAL DEVICE FOR DELIVERY OF THERAPEUTICS - The present disclosure relates to biodegradable intravaginal rings for the delivery of therapeutic or prophylactic agent, inter alia, antiviral agents. The present disclosure further relates to biodegradable polyurethanes which will allow therapeutic/prophylactic agents to be released in a controlled manner that will not degrade when in use, but will degrade upon disposal. | 2010-12-16 |
20100316692 | Product and method for reducing substance craving - A composition and method are provided that are effective for reduction or elimination of the craving foods and other substances for which a patient wishes to reduce consumption or intake. The composition is a paste made of a binder, and non-binder ingredients of mustard, pepper and salt, and optionally a sweetener. The composition of the invention is administered on the tongue as a paste. | 2010-12-16 |
20100316693 | Method for preparing an antimicrobial cotton of cellulose matrix having chemically and/or physically bonded silver and antimicrobial cotton prepared therefrom - There is provided a method for preparing a natural cellulose-AgO matrix having antimicrobial activity without leaching silver from the cellulose-AgO matrix. The method comprises: introducing silver ions (Ag | 2010-12-16 |
20100316694 | NOVEL FILTER COMPOSITES FOR DRUG DETOXIFICATION - A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA. | 2010-12-16 |
20100316695 | CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC AROMATICS OR HETEROAROMATICS - The invention relates to a condensation product obtainable by reaction of
| 2010-12-16 |
20100316696 | LIPOSOME PREPARATION BY SINGLE-PASS PROCESS - The present invention relates to a method of preparing liposomes in a single-pass mode. The method comprises the extusion of a solution or suspension through a porous device and subsequently passing said suspension or solution through a nozzle. Passing the suspension through said nozzle may result in an atomisation of the suspension or solution into droplets which might be employed in a subsequent spray-drying or spray-freezing process. | 2010-12-16 |
20100316697 | METHODS AND COMPOSITIONS FOR DRUG TARGETING - The present invention provides methods and compositions for targeting a drug to a specific desired location, such as an intracellular location in a mammalian cell, by causing said drug to migrate along a pH gradient to the specific location, where the drug preferentially accumulates at a pH range of the specific location. Accordingly, the invention described herein is based on providing a drug which is “pH matched” with that of a particular location, such that the drug preferentially migrates to and accumulates at the pH or pH range at that location. The location may be a type of tissue, a type of cell, a sub-cellular location or an intracellular location, such as an organelle. Without being bound to any theory, the drug migrates along or across a pH gradient, and stops migrating and accumulates at a location of specific pH or range of pH at which the drug is energetically neutral, or where its diffusion potential is at a minimum. | 2010-12-16 |
20100316698 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described. | 2010-12-16 |
20100316699 | Compositions and Methods for Inhibiting Viral Replication - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication. | 2010-12-16 |
20100316700 | SYSTEMIC ADMINISTRATION OF LIPOSOMAL REDUCED GLUTATHIONE FOR THE DECORPORATION OF RADIOACTIVE MATERIALS AND NON-RADIOACTIVE MERCURY - The invention is for the combination and related methods of liposomal reduced glutathione in oral, inhaled, or intravenous, or glutathione inhaled or intravenous, to ameliorate the effects of exposure to or ingestion of radiation or radioactive materials, as treatment to ameliorate the toxic effects of radiation exposure or ingestion and to facilitate the decorporation of radioactive materials such as Co-60. The invention may also be used in conjunction with a decorporation agent such as DTPA, EDTA, DMPS or penicillamine to ameliorate the toxic effects of exposure or ingestion of radioactive agents or other toxic metals. | 2010-12-16 |
20100316701 | COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS - The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart. | 2010-12-16 |
20100316702 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOEITIN EXPRESSION AND AMELIORATING ANEMIA AND STIMULATING ERYTHROPOIESIS - The invention provides compositions (e.g., pharmaceuticals, formulations) and methods for ameliorating (e.g., preventing or treating) an anemia and/or stimulating erythropoiesis and/or EPO erythropoietin synthesis. The invention provides compositions comprising a chimeric protein artificial transcription factor comprising a plurality of (multiple) protein DNA-binding domains, e.g., zinc finger binding domains, specific for the promoter region of an erythropoietin (EPO) gene; a consensus nuclear localization protein sequence; a cell-penetrating peptide sequence; and a transcription activation domain. | 2010-12-16 |
20100316703 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 2010-12-16 |
20100316704 | PLATINUM COMPLEXES AND METHODS OF USE - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 2010-12-16 |
20100316705 | SYSTEM FOR EXSANGUINOUS METABOLIC SUPPORT OF AN ORGAN OR TISSUE - An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed. | 2010-12-16 |
20100316706 | CARBOCYCLIC AND OXACARBOCYCLIC FUMARIC ACID OLIGOMERS - The present invention relates to certain carbocyclic and oxacarbocyclic fumaric acid oligomers and the use thereof for preparing a pharmaceutical preparation as well of pharmaceutical preparations containing these compounds. | 2010-12-16 |
20100316707 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS - A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal. | 2010-12-16 |
20100316708 | Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 2010-12-16 |
20100316709 | ORALLY DISINTEGRATING SOLID PREPARATION - The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of the fine granules is coated with a coating layer comprising hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose and breakage of the fine granules during tableting is suppressed. | 2010-12-16 |
20100316710 | SUSTAINED-RELEASE TABLET COMPOSITION OF PRAMIPEXOLE - A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm | 2010-12-16 |
20100316711 | NIFEDIPINE CONTAINING OPRESS COATED TABLET AND METHOD OF PREPARING SAME - A sustained release nifedipine-containing press coated tablet, which comprises (A) a core comprising nifedipine and a hydrophilic gel-forming high molecular substance, wherein the dissolution of the nifedipine from the core is designed to be delayed: and (B) an outer shell coating said core, which comprises (i) (a) nifedipine and (b) a disintegration suppression substance comprising a pH-independent water-insoluble polymer, wherein the combined contents of (a) and (b) are in the range of 8 to 22% by weight based on the total weight of the outer shell, and (ii) a hydrophilic gel-forming high molecular substance selected from cellulose derivatives and polyvinyl alcohols, wherein the content thereof is in the range of 76 to 95% by weight based on the total weight of the outer shell, which is characterized in that the diameter of said tablet is 7.5 to 8.5 mm, and the thickness thereof is 4.5 to 5.2 mm, and further characterized in that the dissolution rate of nifedipine from said tablet is controlled within a specific range. The tablet of the present invention is miniaturized as compared to the currently-used nifedipine-containing tablets but the dissolution properties and bioavailability of nifedipine therein are not changed. | 2010-12-16 |
20100316712 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration. | 2010-12-16 |
20100316713 | PHARMACEUTICAL COMPOSITION - The application relates to solid pharmaceutical compositions suitable for oral administration comprising an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions. | 2010-12-16 |
20100316714 | METHODS OF TREATING DISEASE WITH RANDOM COPOLYMERS - The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein. | 2010-12-16 |
20100316715 | CHITOSAN COMPOSITION - This invention relates to a cross-linkable chitosan composition comprising chitosan having a degree of deacetylation between 30 and 75%, wherein the chitosan is randomly deacetylated, and a cross-linking agent, wherein the molar ratio of the cross-linking agent to chitosan is 0.2:1 or less based on the number of functional groups in the cross-linking agent and the number of accessible amino groups in the chitosan. The invention also provides a chitosan hydrogel formed therefrom and uses thereof. | 2010-12-16 |
20100316716 | METHOD FOR TREATING HERPES ZOSTER LESIONS - The present invention relates to the treatment of herpes zoster lesions. Compositions comprising an effective amount of a compound selected from the group consisting of potassium aluminum sulfate, potassium aluminum sulfate dodecahydrate, ammonium aluminum sulfate, ammonium aluminum sulfate dodecahydrate, and ammonium chloride are described as well as methods of their use for treatment purposes. | 2010-12-16 |
20100316717 | INJECTABLE HYDROGEL MICROSPHERES FROM AQUEOUS TWO-PHASE SYSTEM - Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution. | 2010-12-16 |
20100316718 | ACTIVATED FOAM - The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, wherein the foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered. The activated foam can be directly or indirectly contacted with a human body to facilitate blood circulation and promote the improvement of physical condition and the cure of diseases. It also has no adverse effect. | 2010-12-16 |
20100316719 | B-1,3-GLUCAN-DERIVED POLYALDEHYDE/POLYAMINE HYDROGEL - The present invention provides a combination product which comprises:
| 2010-12-16 |
20100316720 | Use of an extract from snow algae in cosmetic or dermatological formulations - The present invention relates to the use of an extract from snow algae, especially an extract from | 2010-12-16 |
20100316721 | Granular Sustained Release Preparation and Production Thereof - There is disclosed a novel sustained release granular resin-pharmaceutical composition comprising an ion exchange resin complexed with a pharmaceutical material wherein said complex is embedded into and on the surface of a diffusion barrier material. There is also disclosed a novel process for preparing the granulated complex wherein an aqueous granulating vehicle is employed to form the complex and the granulated product, thereby avoiding the use of coatings and large amounts of organic solvents in the process. | 2010-12-16 |
20100316722 | Pharmaceutical Forms for the Release of Active Compounds - Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa. | 2010-12-16 |
20100316723 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 2010-12-16 |